"Rivaroxaban" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.
| Descriptor ID |
D000069552
|
| MeSH Number(s) |
D02.886.778.727 D03.383.533.640.713 D03.383.903.727
|
| Concept/Terms |
Rivaroxaban- Rivaroxaban
- 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide
|
Below are MeSH descriptors whose meaning is more general than "Rivaroxaban".
Below are MeSH descriptors whose meaning is more specific than "Rivaroxaban".
This graph shows the total number of publications written about "Rivaroxaban" by people in this website by year, and whether "Rivaroxaban" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 3 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 1 | 3 |
| 2017 | 27 | 27 | 54 |
| 2018 | 40 | 23 | 63 |
| 2019 | 19 | 10 | 29 |
| 2020 | 1 | 3 | 4 |
| 2021 | 4 | 2 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Rivaroxaban" by people in Profiles.
-
Subcutaneous injection of mRNA vaccines against severe acute respiratory syndrome coronavirus 2: an option for severe bleeding disorders or anticoagulated patients? Blood Coagul Fibrinolysis. 2021 09 01; 32(6):423-424.
-
Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial. Am Heart J. 2021 12; 242:115-122.
-
Potential Dexamethasone-Direct Oral Anticoagulant Drug Interaction: Is This a Concern in COVID? Ann Pharmacother. 2022 03; 56(3):319-329.
-
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021 06 12; 397(10291):2253-2263.
-
Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial. Am Heart J. 2021 08; 238:1-11.
-
[Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients]. Vopr Virusol. 2021 03 07; 66(1):40-46.
-
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. Am Heart J. 2021 05; 235:12-23.
-
Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era. Semin Respir Crit Care Med. 2021 04; 42(2):308-315.
-
Fatal intracranial haemorrhage in a hypertensive patient with atrial fibrillation and coronavirus disease 2019. Neuroradiol J. 2021 Apr; 34(2):147-150.
-
Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic. Thromb Res. 2021 01; 197:192-194.